Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Director · See Remarks | November 30, 2022 | December 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date November 30, 2022 · Filed December 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 292,872 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Grant · Acquired 3,000 · Balance 292,872 F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022. |
| Common StockSEC Table I · non-derivative | IndirectBy J.P. Gardner Irrevocable Trust | 292,990 |
Reported balance
Holding disclosure · report date 2022-11-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 292,990 |
| Common StockSEC Table I · non-derivative | IndirectBy P.S. Gardner Irrevocable Trust | 359,092 |
Reported balance
Holding disclosure · report date 2022-11-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 359,092 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2022 Filed Dec 2, 2022 21:23 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantCommon Stock | 3,000 | $0.94 | $2,820.00 |
DisclosureSEC source: 0000899243-22-037431 · doc4.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,872 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 01:13 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0000899243-22-027271 · doc4.xml · derivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2032-07-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022. Read SEC document |
| May 31, 2022 Filed Jun 6, 2022 20:05 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantCommon Stock | 3,000 | $0.99 | $2,970.00 |
DisclosureSEC source: 0000899243-22-021184 · doc4.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,872 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of December 1, 2021 through May 31, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:23 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 162,500 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000899243-22-018817 · doc4.xml · derivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2032-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:31 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0000899243-22-006830 · doc4.xml · derivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2032-02-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 14,340 | $6.73 | $96,508.20 |
DisclosureSEC source: 0000899243-21-036599 · doc4.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,872 F1 · kind: This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 23:40 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036335 · doc4.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,212 F1 · kind: On February 11, 2021, the reporting person was granted 100,000 restricted stock units. The restricted stock units vest in two equal installments subject to the achievement of certain performance milestones related to the issuer's business plans. The first performance milestone was achieved, resulting in vesting of 50,000 restricted stock units and the corresponding issuance of 50,000 shares of issuer common stock. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:33 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0000899243-21-031272 · doc4.xml · derivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-08-01 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on August 2, 2021. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:46 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0000899243-21-006710 · doc4.xml · derivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:07 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000899243-20-004301 · doc4.xml · derivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020. Read SEC document |
| January 10, 2020 Filed Jan 10, 2020 22:01 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 11,200 | $15.25 | $170,800.00 |
DisclosureSEC source: 0001562180-20-000327 · primarydocument.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,212 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:01 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 2,800 | $15.10 | $42,280.00 |
DisclosureSEC source: 0001562180-20-000118 · primarydocument.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,412 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| December 23, 2019 Filed Dec 23, 2019 21:41 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 2,897 | $15.10 | $43,754.55 |
DisclosureSEC source: 0001562180-19-006252 · primarydocument.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,212 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 23:22 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 76,711 | $15.16 | $1,162,616.57 |
DisclosureSEC source: 0001562180-19-006221 · primarydocument.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,109 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 22:08 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 4,392 | $15.10 | $66,319.20 |
DisclosureSEC source: 0001562180-19-006078 · primarydocument.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,820 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 20:02 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 12,331 | $15.11 | $186,321.41 |
DisclosureSEC source: 0001562180-19-003623 · primarydocument.xml · nonDerivative · entry 2 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,212 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:02 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 1,669 | $15.10 | $25,201.90 |
DisclosureSEC source: 0001562180-19-003623 · primarydocument.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,543 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 182,900 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002869 · doc4.xml · derivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,900 Underlying: Common Stock · 182,900 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries C Preferred Stock · Derivative | 21,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 8 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By J.P. Gardner Irrevocable Trust Disclosed balance after: 0 Underlying: Common Stock · 8,304 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries B Preferred Stock · Derivative | 19,314 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 7 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By P.S. Gardner Irrevocable Trust Disclosed balance after: 0 Underlying: Common Stock · 7,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries B Preferred Stock · Derivative | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 6 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By J.P. Gardner Irrevocable Trust Disclosed balance after: 0 Underlying: Common Stock · 5,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries A Preferred Stock · Derivative | 36,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 5 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By P.S. Gardner Irrevocable Trust Disclosed balance after: 0 Underlying: Common Stock · 14,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries A Preferred Stock · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 4 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By J.P. Gardner Irrevocable Trust Disclosed balance after: 0 Underlying: Common Stock · 11,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | PurchaseCommon Stock | 400 | $15.00 | $6,000.00 |
DisclosureSEC source: 0000899243-18-018316 · doc4.xml · nonDerivative · entry 3 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,212 F2 · shares: Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionCommon Stock | 21,677 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018316 · doc4.xml · nonDerivative · entry 2 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By P.S. Gardner Irrevocable Trust Disclosed balance after: 359,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionCommon Stock | 25,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018316 · doc4.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By J.P. Gardner Irrevocable Trust Disclosed balance after: 292,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.